- Home
- MTA vs AVR Comparison
MTA vs AVR Comparison
Compare MTA & AVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTA
- AVR
- Stock Information
- Founded
- MTA 1983
- AVR 1999
- Country
- MTA Canada
- AVR Australia
- Employees
- MTA N/A
- AVR N/A
- Industry
- MTA
- AVR
- Sector
- MTA
- AVR
- Exchange
- MTA Nasdaq
- AVR NYSE
- Market Cap
- MTA 267.2M
- AVR 241.5M
- IPO Year
- MTA N/A
- AVR 2024
- Fundamental
- Price
- MTA $2.92
- AVR $3.64
- Analyst Decision
- MTA Hold
- AVR Strong Buy
- Analyst Count
- MTA 1
- AVR 4
- Target Price
- MTA $4.50
- AVR $16.50
- AVG Volume (30 Days)
- MTA 373.5K
- AVR 273.4K
- Earning Date
- MTA 05-14-2025
- AVR 05-16-2025
- Dividend Yield
- MTA N/A
- AVR N/A
- EPS Growth
- MTA N/A
- AVR N/A
- EPS
- MTA N/A
- AVR N/A
- Revenue
- MTA $5,882,000.00
- AVR $2,703,000.00
- Revenue This Year
- MTA $37.69
- AVR $37.33
- Revenue Next Year
- MTA $120.61
- AVR $141.49
- P/E Ratio
- MTA N/A
- AVR N/A
- Revenue Growth
- MTA 28.55
- AVR N/A
- 52 Week Low
- MTA $2.32
- AVR $3.50
- 52 Week High
- MTA $4.08
- AVR $8.79
- Technical
- Relative Strength Index (RSI)
- MTA 47.01
- AVR N/A
- Support Level
- MTA $2.95
- AVR N/A
- Resistance Level
- MTA $3.11
- AVR N/A
- Average True Range (ATR)
- MTA 0.13
- AVR 0.00
- MACD
- MTA 0.00
- AVR 0.00
- Stochastic Oscillator
- MTA 31.71
- AVR 0.00
About MTA Metalla Royalty & Streaming Ltd.
Metalla Royalty & Streaming Ltd is a precious metals royalty and streaming company, which engages in the acquisition and management of precious metal royalties, streams, and similar production-based interests. It's a pure-play gold and silver streaming and royalty company. It generates revenue from royalties, streams, and other interests.
About AVR ANTERIS TECHNOLOGIES GLOBAL CORP
Anteris Technologies Global Corp. is a structural heart company committed to discovering, developing and commercializing medical devices designed to improve the quality of life for patients with aortic stenosis. Its product, the DurAVR THV system, represents a product opportunity in a new THV class of single-piece heart valves, for the treatment of aortic stenosis. Its DurAVR THV system consists of a single-piece, biomimetic valve made with its proprietary ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold.